Following a thorough and independent review, the Therapeutic Goods Administration (TGA) has found that the Pfizer/BioNTech COVID-19 vaccine candidate, Comirnaty, meets the strict safety and efficacy standards required for provisional approval. It is now provisionally approved for use in those aged 16 years or older for active immunisation to prevent COVID-19 disease.

For more information please refer to the links below:

TGA provisionally approves Pfizer COVID-19 vaccine

COVID-19 vaccine: Pfizer Australia – COMIRNATY BNT162b2 (mRNA)

For more information on the provisional pathway of vaccine approval, please refer to our reference page below:

MVEC: Provisional registration of COVID-19 vaccine(s) in Australia